Navigation Links
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Date:9/5/2008

al activity of belinostat has been observed in an ongoing Phase II trial of belinostat monotherapy in patients with recurrent or refractory cutaneous (CTCL) or peripheral T-cell lymphoma (PTCL). Efficacy is being analyzed separately in PTCL and CTCL patients. In 11 patients evaluable for response in the PTCL arm, 2 durable complete responses (CR) and 4 Stable Diseases (SD) have been observed as announced at "10th International Conference on Malignant Lymphoma" in Lugano in June. In both arms of the study, the objective response rate in the first stage has met the criteria for expansion to the second stage of a Simon 2-stage design.

Objectives and methods of evaluation The primary study endpoint will be objective response rate (ORR). Objective response is complete response (CR) or partial response (PR) based on independent radiology review. Secondary objectives of the study are to determine: safety of belinostat monotherapy, time to response, duration of response, time to progression (TTP), progression-free survival (PFS), one-year progression-free rate, one-year survival rate and overall survival (OS).

Today's news does not change TopoTarget's full-year financial guidance for 2008.

Background information

About Periferal T-Cell Lymphomas (PTCL)

PTCL represent approximately 10% of all non-Hodgkin's lymphomas (NHL) in Western populations and are associated with a poor prognosis. Most patients with PTCL relapse after initial treatment with cytotoxic agents, and 5-year survival is less than 30%. T-cell Non Hodkins Lymphomas, to which PTCL belongs, are associated with a poorer outcome and survival compared to the B-cell lymphomas. The primary response rate for all PTCL subtypes remains at less than 60%, with nearly all patients relapsing. Median survival of all PTCL patients (excluding a few subtypes) is approximately 3-4 years, with a 5-year survival of less than 30%. There are currently no therapies approved specifically for PTCL. Prim
'/>"/>

SOURCE TopoTarget
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
2. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
5. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
8. Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
9. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
10. QLT announces positive Health Canada decision on Aczone(R)
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
(Date:8/29/2014)... one of the most promising technologies for future quantum ... (photons) instead of electrons. First, it is necessary to ... and control their direction. Researchers around the world have ... but now scientists at the Niels Bohr Institute have ... one at a time and in a particular direction. ...
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... presentations to be hosted at 2008 American Association for ... Clinical Chemistry Annual ... invited investors to participate in the Company,s Analyst,Reception which is ... for Clinical Chemistry (AACC) Annual Meeting., Cepheid speakers will ...
... while also encouraging sharing of IP, technologies, partnerships ... and other key ... elimination of duplications and increased scale in the ... operate as an independent research and early development center and ...
... QINGDAO, China and ROCKVILLE, Md., July 18 /Xinhua-PRNewswire/ ... infant,formula company in China, and a producer, marketer ... adults, announced today that,it has postponed its proposed ... to current stock market conditions, our board has ...
Cached Biology Technology:Cepheid to Webcast Analyst Event 2Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 2Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 3Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 4Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 5Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 6Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 7Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 8Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 9Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 10Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 11Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 12Synutra Announces Postponement of Proposed Offering 2
(Date:8/29/2014)... little has been known about what genetic changes transform ... scientists, one of whom is a University of Montana ... genes controlling the development of the brain and the ... study was published Aug. 28 in Science ... online at http://www.sciencemag.org/ ., The domestication of animals ...
(Date:8/29/2014)... the University of Texas Medical Branch at Galveston has gone ... can completely protect monkeys against a lethal dose of Ebola ... when the disease is severe. , Thomas Geisbert, professor of ... discussing advances in Ebola treatment research. The filoviruses known ... deadly of pathogens, with fatality rates of up to 90 ...
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2CCNY team defines new biodiversity metric 2
... be highlighted at the 35 th annual Citrus Postharvest ... Riverside Extension April 23 and 24 in Santa Barbara. ... April 23, and 8 a.m. to noon Wednesday, April 24, at ... include a large segment on food safety as well as an ...
... NEW YORK , April 16, 2013 Today, ... identity authentication solutions, announced a partnering relationship with ... solely to the financial services industry, to implement EyeLock,s ... Capco recently launched its Secure – Banking ...
... strain that transferred to Haiti in 2010 has multiple toxin ... and is evolving to be more like an 1800s version ... The strain, "altered El Tor," which emerged around 2000, ... severe diarrhea and dehydration than earlier strains that had been ...
Cached Biology News:Conference to highlight latest in postharvest pest control 2Capco Partners with EyeLock to Bring Iris Biometric Security to Banks 2Capco Partners with EyeLock to Bring Iris Biometric Security to Banks 3Haiti cholera mutations could lead to more severe disease 2Haiti cholera mutations could lead to more severe disease 3
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
... Mount is formulated for covering tissue sections and cell preparations ... end products. , ... Application: ... or AEC that require an aqueous mounting medium, or those ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... Retrieval Solution, pH 9 (x 10) ... 9, intended for heat-induced target retrieval prior ... for use on formalin-fixed, paraffin-embedded tissue sections ... mol/L citrate buffer, pH 6, the use ...
Biology Products: